| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/17435390.2018.1459922 |
| P8608 | Fatcat ID | release_hrbpwsoq6ndldjuefnfsiehvky |
| P932 | PMC publication ID | 6051695 |
| P698 | PubMed publication ID | 29658401 |
| P50 | author | Zhoumeng Lin | Q55095179 |
| Nancy A Monteiro-Riviere | Q55948798 | ||
| Yi-Hsien Cheng | Q56678798 | ||
| Jim E Riviere | Q88367444 | ||
| P2093 | author name string | Nancy A Monteiro-Riviere | |
| Jim E Riviere | |||
| Yi-Hsien Cheng | |||
| Zhoumeng Lin | |||
| P2860 | cites work | Advances in inhalation dosimetry models and methods for occupational risk assessment and exposure limit derivation | Q23912442 |
| Adverse effects of citrate/gold nanoparticles on human dermal fibroblasts | Q40256791 | ||
| Quantitative biokinetics of titanium dioxide nanoparticles after intratracheal instillation in rats: Part 3. | Q40293855 | ||
| Quantitative biokinetics of titanium dioxide nanoparticles after oral application in rats: Part 2. | Q40293864 | ||
| Quantitative biokinetics of titanium dioxide nanoparticles after intravenous injection in rats: Part 1. | Q40293879 | ||
| A physiologically based pharmacokinetic model for polyethylene glycol-coated gold nanoparticles of different sizes in adult mice | Q40952736 | ||
| Size and Concentration Effect of Gold Nanoparticles on X-ray Attenuation As Measured on Computed Tomography | Q41857072 | ||
| Predicting the impact of biocorona formation kinetics on interspecies extrapolations of nanoparticle biodistribution modeling | Q42462263 | ||
| Of mice, men and nanoparticle biocoronas: are in vitro to in vivo correlations and interspecies extrapolations realistic? | Q44403669 | ||
| Protein corona modulation of hepatocyte uptake and molecular mechanisms of gold nanoparticle toxicity | Q46454818 | ||
| Integration of Genome Scale Metabolic Networks and Gene Regulation of Metabolic Enzymes With Physiologically Based Pharmacokinetics | Q47158582 | ||
| Combining transcriptomics and PBPK modeling indicates a primary role of hypoxia and altered circadian signaling in dichloromethane carcinogenicity in mouse lung and liver | Q47799113 | ||
| Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats | Q48359484 | ||
| Biocorona formation on gold nanoparticles modulates human proximal tubule kidney cell uptake, cytotoxicity and gene expression. | Q50708170 | ||
| Surface chemistry of gold nanoparticles determines the biocorona composition impacting cellular uptake, toxicity and gene expression profiles in human endothelial cells | Q50719032 | ||
| Mechanisms of cell uptake, inflammatory potential and protein corona effects with gold nanoparticles | Q51306137 | ||
| Integration of genome-scale metabolic networks into whole-body PBPK models shows phenotype-specific cases of drug-induced metabolic perturbation | Q52672914 | ||
| Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles | Q53421447 | ||
| Gold nanoparticles induce apoptosis, endoplasmic reticulum stress events and cleavage of cytoskeletal proteins in human neutrophils | Q54235140 | ||
| In vivo toxicity, biodistribution, and clearance of glutathione-coated gold nanoparticles | Q84540926 | ||
| Using physiologically based pharmacokinetic (PBPK) modeling for dietary risk assessment of titanium dioxide (TiO2) nanoparticles | Q87437580 | ||
| A simple practice guide for dose conversion between animals and human | Q26750843 | ||
| Gold nanoparticles as novel agents for cancer therapy | Q27008020 | ||
| An integrated approach for the in vitro dosimetry of engineered nanomaterials | Q28386114 | ||
| To scale or not to scale: the principles of dose extrapolation | Q28751735 | ||
| An Agent-Based Model of a Hepatic Inflammatory Response to Salmonella: A Computational Study under a Large Set of Experimental Data | Q30000073 | ||
| Nanoparticles-protein interaction: Role in protein aggregation and clinical implications | Q30394144 | ||
| Time evolution of the nanoparticle protein corona. | Q33606003 | ||
| Assessment of the In Vivo Toxicity of Gold Nanoparticles | Q33948983 | ||
| PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals | Q34124141 | ||
| ISDD: A computational model of particle sedimentation, diffusion and target cell dosimetry for in vitro toxicity studies | Q34451016 | ||
| Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration | Q34634591 | ||
| Size-dependent in vivo toxicity of PEG-coated gold nanoparticles | Q35234739 | ||
| Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. | Q35703091 | ||
| Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future | Q35942437 | ||
| Probabilistic modelling of prospective environmental concentrations of gold nanoparticles from medical applications as a basis for risk assessment | Q36398030 | ||
| Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments | Q36650976 | ||
| A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles | Q37167472 | ||
| Structure-activity relationships for biodistribution, pharmacokinetics, and excretion of atomically precise nanoclusters in a murine model | Q37407872 | ||
| Toxicity and Biokinetics of Colloidal Gold Nanoparticles | Q37646378 | ||
| Air-blood barrier translocation of tracheally instilled gold nanoparticles inversely depends on particle size | Q37651373 | ||
| Interaction of engineered nanoparticles with various components of the environment and possible strategies for their risk assessment | Q37803451 | ||
| Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies | Q37809976 | ||
| Engineered nanomaterial risk. Lessons learnt from completed nanotoxicology studies: potential solutions to current and future challenges | Q38057778 | ||
| Pharmacokinetics of metallic nanoparticles. | Q38260360 | ||
| The concept of bio-corona in modulating the toxicity of engineered nanomaterials (ENM). | Q38642323 | ||
| Development and application of a population physiologically based pharmacokinetic model for penicillin G in swine and cattle for food safety assessment | Q38719739 | ||
| Preparation, characterization, and in vitro dosimetry of dispersed, engineered nanomaterials | Q38720595 | ||
| Performance Assessment and Translation of Physiologically Based Pharmacokinetic Models from acslX™ to Berkeley Madonna™, MATLAB®, and R language: Oxytetracycline and Gold Nanoparticles as Case Examples. | Q38731345 | ||
| The applicability of conventional cytotoxicity assays to predict safety/toxicity of mesoporous silica nanoparticles, silver and gold nanoparticles and multi-walled carbon nanotubes | Q38740448 | ||
| Assessing exposure risks for freshwater tilapia species posed by mercury and methylmercury | Q38864500 | ||
| A computational framework for interspecies pharmacokinetics, exposure and toxicity assessment of gold nanoparticles | Q38933494 | ||
| Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles | Q39005101 | ||
| Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. | Q39921419 | ||
| P433 | issue | 5 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| probabilistic risk assessment | Q1082833 | ||
| P304 | page(s) | 453-469 | |
| P577 | publication date | 2018-04-14 | |
| P1433 | published in | Nanotoxicology | Q1964708 |
| P1476 | title | Probabilistic risk assessment of gold nanoparticles after intravenous administration by integrating in vitro and in vivo toxicity with physiologically based pharmacokinetic modeling | |
| P478 | volume | 12 |
Search more.